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The receptor tyrosine kinase superfamily comprises many cell-surface receptors includ-
ing the insulin receptor (IR) and type 1 insulin-like growth factor receptor (IGF1R) that are 
constitutively homodimeric transmembrane glycoproteins. Therefore, these receptors 
require ligand-triggered domain rearrangements rather than receptor dimerization for 
activation. Specifically, binding of peptide ligands to receptor ectodomains transduces 
signals across the transmembrane domains for trans-autophosphorylation in cytoplas-
mic kinase domains. The molecular details of these processes are poorly understood in 
part due to the absence of structures of full-length receptors. Using MD simulations and 
enhanced conformational sampling algorithms, we present all-atom structural models of 
peptides containing 51 residues from the transmembrane and juxtamembrane regions 
of IR and IGF1R. In our models, the transmembrane regions of both receptors adopt 
helical conformations with kinks at Pro961 (IR) and Pro941 (IGF1R), but the C-terminal 
residues corresponding to the juxtamembrane region of each receptor adopt unfolded 
and flexible conformations in IR as opposed to a helix in IGF1R. We also observe 
that the N-terminal residues in IR form a kinked-helix sitting at the membrane–solvent 
interface, while homologous residues in IGF1R are unfolded and flexible. These con-
formational differences result in a larger tilt-angle of the membrane-embedded helix 
in IGF1R in comparison to IR to compensate for interactions with water molecules at 
the  membrane–solvent interfaces. Our metastable/stable states for the transmembrane 
domain of IR, observed in a lipid bilayer, are consistent with a known NMR structure of 
this domain determined in detergent micelles, and similar states in IGF1R are consistent 
with a previously reported model of the dimerized transmembrane domains of IGF1R. 
Our all-atom structural models suggest potentially unique structural organization of 
kinase domains in each receptor.
Keywords: molecular dynamics simulations, transmembrane domains, insulin receptor, insulin-like growth factor 
receptor, cell signaling, diabetes
1. inTrODUcTiOn
Insulin receptor (IR) and type 1 insulin-like growth factor receptor (IGF1R) are homologous, ligand-
activated, and constitutively homo-dimeric transmembrane glycoproteins of the receptor tyrosine 
kinase (RTK) superfamily (1). Both IR and IGF1R have similarities in primary sequences, structural 
topologies, functions, and binding affinities for peptide ligands such as insulin and insulin-like 
growth factors (IGFs) (2–13). Structurally, each subunit in receptors is composed of three large 
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protein fragments: the extracellular part (also known as the 
ectodomain), the intracellular part (containing kinase domains), 
and a single-pass transmembrane domain (TMD) that connects 
extracellular and intracellular fragments. Specifically, the TMD as 
well as the catalytic kinase domain are located in the β-chains of 
each subunit of receptor homodimers.
TMD potentially plays a critical role in mediating signaling via 
IR and IGF1R because ligand binding to extracellular subunits 
leads to conformational changes that are conveyed (via TMD) to 
kinase domains, thereby triggering trans-autophosphorylation 
and downstream signaling cascades (14–20). Initially, the TMD 
appeared to play a passive role in insulin signaling (21) but other 
studies indicate that modifications in TMDs of IR or IGF1R alter 
receptor internalization as well as affect kinase activation and 
negative cooperativity (22–25), while replacing IR–TMD with 
that of glycophorin A inhibits insulin action (26). The mecha-
nistic details of these processes remain poorly understood at 
the molecular scale, but simple mechanical models for signal 
transduction via TMD suggest that a lateral shift or a rotational 
motion of TMD is energetically more favorable than the verti-
cal motion in the phospholipid bilayer, as it would suggest 
dimerization of TMDs that could bring kinase domains in 
proximity (25, 27–29). However, recent studies propose different 
mechanisms for IR and IGF1R activation (3, 30): Lee et al. (31) 
have suggested that TMDs of IR in the non-activated basal state 
are constitutively dimerized and dissociate on ligand binding, 
while Kavran et al. (32) have suggested that ligand binding leads 
to dimerization of TMDs in IGF1R. Previously, a different “yo-yo” 
model of receptor activation was proposed by Ward et al. (10) in 
which the ligand-induced conformational change releases kinase 
domains (for transphosphorylation) from an initially constrained 
position near the membrane. These studies do not directly sup-
port a common mechanism of activation of transmembrane 
cell-surface receptors (27).
Therefore, the exact mechanism of signal transduction in IR 
and IGF1R remains elusive in part due to the lack of knowledge of 
intact structures of full-length receptors (in apo or ligand-bound 
forms) although several structures of excised extracellular and 
intracellular domains have been solved (33–48). The solution 
structure of IR–TMD has been determined in detergent micelles 
(49), but the deviation of the hydrophobic thickness of micelles 
from lipid bilayers can potentially cause changes in protein 
conformations (50). Nonetheless, this study suggested that the 
excised IR–TMD sequence remains largely monomeric in solu-
tion and forms an α-helix with a kink at residues Gly960 and 
Pro961, but the possibility of dimer formation was not excluded 
depending upon the detergent/protein ratio. It was also specu-
lated that the presence of one SXXXG sequence motif in IR–TMD 
could play a role in dimerization similar to the GXXXG motif 
(51, 52). Currently, no experimental data on the structure of 
IGF1R–TMD are available.
We have previously shown that molecular dynamics (MD) 
simulations conducted in explicit solvent with all-atom structural 
models and enhanced sampling algorithms (53) are highly prom-
ising tools to understand conformational flexibility of receptor 
structures and their ligand-binding mechanisms (8,  54–58). 
In this work, we aim to study the structure, orientation, and 
conformational variability of TMDs of IR and IGF1R in an 
explicit lipid bilayer environment. In particular, we have studied 
the folding/unfolding behavior and stability of membrane-
embedded peptide sequences of IR and IGF1R using enhanced 
sampling simulations conducted with metadynamics algorithm 
(59) because classical MD simulations are likely insufficient for 
sampling of all relevant peptide conformations in the lipid bilayer. 
In particular, our predicted structural ensembles are consistent 
with recent NMR data (49) and reveal that the presence of Gly960 
and Pro961 in IR–TMD indeed results in increased flexibility 
in comparison to IGF1R–TMD, while metastable structural 
ensembles of both peptides show significant differences in their 
orientation in the membrane and in conformations of the N- and 
C-termini. We also observe different patterns of water distribu-
tion near peptide residues at the membrane–solvent interface 
and find that changes in backbone conformations of peptides 
correlate with certain angle variables measured relative to the 
membrane normal.
2. MaTerials anD MeThODs
2.1. Molecular Dynamics simulations: 
system setup
All MD trajectories were generated with NAMD (60) using 
the TIP3P water model and the CHARMM force-field with the 
CMAP correction (61, 62). VMD was used for system creation, 
protein rendering, and analyses (63). All simulations were car-
ried out in the NPT ensemble using the Langevin thermostat at 
310 K and the Nosé-Hoover barostat. We modeled 51 residues for 
IR (939 – FYVTDYLDVPSNIAKIIIGPLIFVFLFSVVIGSIYLFL 
RKRQPDGPLG – 989) and IGF1R (918 – DPVFFYVQAKTGY 
ENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLG – 968) 
that included the predicted TMD sequence (underlined; 957–979 
for IR and 936–959 for IGF1R) for each receptor (Sequence 
numbering is based upon protein knowledgebase www.uniprot.
org accession numbers P06213 and P08069). For each sequence, 
we generated an ideal α-helix as a starting structure using VMD’s 
psfgen tool and generated a palmitoyloleoylphosphatidylcholine 
(POPC) membrane patch of ~80 Å × 80 Å in size using VMD’s 
membrane builder tool. Each peptide was then embedded in the 
POPC bilayer by aligning the centers of mass and the principal 
axis of each helix along the z-direction. Thereafter, overlapping 
lipid molecules within 2  Å of each peptide were deleted. Each 
system was solvated with ~17700 water molecules, neutralized 
with KCl, and brought to an ionic strength of 0.2M. The final 
simulation domains measured ~83  Å  ×  80  Å  ×  140  Å and 
contained 74168 (IR) and 74144 (IGF1R) atoms, respectively. 
Each system was then equilibrated in three consecutive steps. 
In the first step, initially a conjugate-gradient minimization 
was carried out for 1000 cycles, which was followed by a short 
MD equilibration (0.5 ns long with a 2-fs time step) by keeping 
all atoms fixed except those in lipid tails. In the second step, 
MD equilibration was continued for 5 ns in the NPT ensemble 
by fixing only peptide atoms. In the third step, no atoms were 
fixed or constrained in a 50  ns MD equilibration in the NPT 
ensemble. The final atomic coordinates after the equilibration in 
the third step were used to setup enhanced exploration of peptide 
AB
FigUre 1 | (a) Initial configurations of IR–TMD and IGF1R–TMD in 
membrane and solvent environments. Lipid and water molecules are shown 
in black and cyan wireframe representations, respectively. Peptides are 
shown as gray cartoons with the predicted TMD sequence rendered in blue. 
Two proline residues at the N-terminus of each peptide are shown in red 
space-filling representations. (B) Peptide configurations at the end of MD 
equilibration step 3 (see Materials and Methods).
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conformations in lipids using metadynamics, as described below. 
Initial and equilibrated configurations of IR–TMD and IGF1R–
TMD are shown in Figure 1.
2.2. Metadynamics simulations
Metadynamics is an enhanced sampling method for faster and 
uniform exploration of conformational space in a specified set 
of collective variables (CVs) by augmenting the force-field with 
a history-dependent biasing potential (Vmeta) of the following 
form (59, 64):
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where ξi is the current value of the CV, and ξi(t′) is the value of 
the CV at time t′. Vmeta is constructed as a sum of Ncv-dimensional 
repulsive Gaussian functions with a chosen height (W) and 
width (δ). The Gaussian functions can be added at a desired 
frequency τG. These three main parameters in metadynamics (W, 
δ, and τG) control the efficiency and accuracy of the free energy 
reconstruction from converged metadynamics potential (Vmeta) 
(65). Metadynamics has been successfully applied to study many 
biophysical problems (66–72) including prediction of peptide 
conformations in lipid membranes (73, 74).
In this work, we have used as CV the root-mean-squared-
deviation (RMSD) of the backbone Cα atoms with respect to a 
perfect α-helix. The RMSD CV was bounded between 0 and 15 Å, 
and therefore, low values of RMSD indicate helical conforma-
tions and higher values indicate kinks and/or unfolded states. 
For all metadynamics simulations, a 1-fs integration time step 
was used, and the Gaussian height (W), width (δ), and frequency 
(τG) of 0.1  kcal/mol, 0.2  Å, and 1  ps, respectively, were used. 
Metadynamics simulations converged in 160 (IR–TMD) and 
145 ns (IGF1R–TMD), respectively, after which each trajectory 
sampled the CV range diffusively. The converged free-energy 
profiles from the last 10 ns of each metadynamics trajectory were 
used for analyzing metastable conformations and for carrying out 
other analyses reported in this work. We note that we have not 
studied the effect of including multiple CVs in our simulations. 
Additionally, we point out that the protonation states of all resi-
dues were assigned at physiological pH, and the effect of varying 
pH was not explicitly studied here.
3. resUlTs
3.1. Free energy Profiles and 
conformational ensembles of ir–TMD  
and igF1r–TMD
Starting with a perfectly α-helical conformation of each peptide 
(Figure 1A), we carried out independent ~55 ns long MD equi-
librations in explicit membrane and solvent environments before 
launching enhanced sampling simulations using metadynamics 
(see Materials and Methods). The final conformations of peptides 
sampled from these MD trajectories (Figure 1B) show that even 
at these short-timescales, peptides deviate from their initial con-
formations and adopt tilted conformational states with respect to 
the membrane normal. Specifically, IR–TMD largely maintains 
an α-helical structure but with a sharp kink at Pro961 such that 
residues 939–958 in the N-terminal helix interact strongly with 
lipids than the water molecules. IGF1R–TMD also remains 
α-helical with a minor kink at Pro941, but the first 10 residues 
in the N-terminus spontaneously unfold and interact with the 
water molecules. The Cα-RMSDs relative to a perfect helix for the 
final peptide conformations are 6.35  Å (IR–TMD) and 3.75  Å 
(IGF1R–TMD), respectively.
To uniformly explore peptide conformations between 0 and 
15 Å RMSD and to obtain estimates on the free energy, we carried 
out 160 ns (IR–TMD) and 145 ns (IGF1R–TMD) long metady-
namics simulations (see Materials and Methods). Consistent 
with enhanced conformational sampling, each peptide visited 
both helical and non-helical states multiple times during these 
simulations. The averaged free energy profiles (potentials of mean 
force; PMFs) from the last 10 ns of each metadynamics trajectory 
(Figures  2A,B) indicate that peptide conformations below an 
RMSD of ~3.5 Å and above ~11.5 Å are significantly higher in free 
energy relative to other states. This suggests that peptides prefer 
neither a fully helical structure (which occurs at 0 Å RMSD) nor 
a significantly unfolded configuration (which occurs beyond 
12 Å RMSD), but instead metastable/stable configurations likely 
contain both helical and partially unfolded structural motifs. 
Moreover, the stable conformations with the lowest free-energy 
relative to other states occur at ~6  Å RMSD for IR–TMD and 
~8 Å RMSD for IGF1R–TMD (inset in Figures 2A,B).
From the last 10 ns of each metadynamics trajectory, we har-
vested several metastable/stable configurations for each peptide 
A C
DB
FigUre 2 | (a,B) Averaged potentials of mean force (PMFs) from the last 10 ns of metadynamics simulations for IR–TMD (top) and IGF1R–TMD (bottom) in a lipid 
membrane. Free energy profiles show relatively small energetic differences (~2–3 kcal/mol) in a wide range (5–11 Å) of RMSD, as indicated by magnified profiles 
(inset). Shaded regions on PMF traces indicate computed statistical variation in free energy profiles. (c,D) Overlay of all metastable/stable conformations for IR–TMD 
and IGF1R–TMD in gray cartoon representations except the transmembrane sequence, which is displayed in blue cartoons. All depicted conformations are aligned 
on the initial configuration of each peptide (shown in Figure 1a) with alignment based upon residues in the predicted transmembrane sequence (blue cartoon). 
Pro961 (IR–TMD) and Pro941 (IGF1R–TMD) are shown in red, and Gly960 (IR) in green space-filling representations, respectively. Horizontal lines indicate the 
approximate location of the lipid bilayer.
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(17 for IR and 11 for IGF1R) with a ~2–3 kcal/mol free-energy 
difference. These conformations for IR–TMD and IGF1R–TMD 
are distinct (Figures 2C,D) and have the following features: (1) in 
IR–TMD, α-helical structures are observed for residues 939–958 
in the N-terminus and residues 962–980 (part of the predicted 
transmembrane domain sequence, 957–980, of IR). These two 
helices are stably held together by a sharp kink at Gly960 and 
Pro961. The remaining residues in the C-terminus (981–989) 
are highly flexible and adopt unfolded conformations; and (2) in 
IGF1R–TMD, the N-terminal residues 918–932 are significantly 
flexible and unfolded, a small α-helix kinked at Pro941 is observed 
between 933 and 941, while a full α-helix is observed for residues 
942–968. To quantify these observations, we further carried out 
secondary structure analysis on all metastable/stable configura-
tions and computed average helicity on a per residue basis. These 
results (Figure 3) show that the α-helical content for IR–TMD 
is reduced between residues 939 and 942, and no helical content 
is observed between residues 959–961 and 982–989, while for 
IGF1R–TMD, no helical content is present between residues 918 
and 931, and a minor decrease in helicity is observed at residue 
Gly950. We note that an unstable kink at Gly950 mostly switches 
back to a stable α-helix, as described in the following.
3.2. Orientation of ir–TMD and  
igF1r–TMD in the Membrane
In metadynamics simulations, the change in RMSD of peptides 
relative to a perfect helix could be due to several different types 
of structural features such as tilting, bending, or unfolding. 
Therefore, to understand the orientation of peptides in the lipid 
bilayer, we computed three angle variables and analyzed their cor-
relation with the RMSD change (Figure 4). For IR–TMD, α and 
β characterize the orientation (relative to the membrane normal) 
of the helix preceding Pro961 and the helix corresponding to 
the transmembrane sequence (962–979), and γ characterizes the 
interhelical angle, while in IGF1R–TMD, α and β characterize the 
orientation of helices between 934–948 and 951–966 relative to 
the membrane normal, and γ is the interhelical angle.
These data (Figures 4B,D) indicate that several conformations 
in the RMSD range (0–15 Å) can take a wide variety of angle values 
AB
FigUre 3 | averaged percentage helicity per residue for all 
metastable/stable conformations of ir–TMD (a) and igF1r–TMD (B).
FigUre 4 | Two angle collective variables relative to the membrane normal and one between the helices are shown to quantify peptide orientations 
in a lipid bilayer: (a,B) ir–TMD and (c,D) igF1r–TMD. Correlations of angles with RMSD are shown in (B,D). Scattered blue dots indicate all values of angles 
explored via metadynamics trajectories, and red lines are the best fit curves. Black dots are angles corresponding to metastable/stables conformations shown in 
Figures 2c,D.
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suggesting multiple orientations of peptides due to enhanced 
conformational sampling via metadynamics. For IR–TMD, we 
find that angles α and γ are correlated with RMSD such that an 
increase in RMSD results in an increase in α but a decrease in γ. 
Structurally, this means that the N-terminal helix in IR–TMD 
kinks toward the membrane, thereby becoming parallel to the 
membrane–solvent interface, while the membrane-embedded 
helix straightens to align along the membrane normal, as also 
indicated by a sharp decrease in β. For the metastable/stable 
conformations of IR (Figure 2C), we observe α values between 
~70° and 90°, γ values slightly smaller than ~110°, and β values 
between ~5° and 25°. For IGF1R–TMD, we observe no significant 
correlation between the angle α and RMSD as α remains near 30° 
on average, suggesting that the helix between residues 934 and 
948 remains tilted relative to the membrane normal. However, 
an increase in RMSD is correlated with a decrease in β and γ that 
leads to a kink at Gly950. This kink is unstable and not observed 
in metastable/stable conformations of IGF1R–TMD (Figure 2D) 
where γ values near 180° are observed. In these IGF1R–TMD 
conformations, a significant contribution to change in RMSD is 
due to the unfolding of the N-terminus (residues 918–932), and 
a minor contribution is due to a kink at Pro941.
3.3. interactions of Peptides with 
the solvent
In each 51-residue long peptide studied here, several charged 
amino acids are present in the sequence preceding as well as 
following the predicted TMD sequence (957–979 for IR and 
936–959 for IGF1R). Because we observed kinked or unstruc-
tured configurations in the termini of each peptide, we analyzed 
all metastable conformations for interactions with water mol-
ecules at the membrane–solvent interface. Specifically, we present 
average number of water molecules within 4.5 Å of each protein 
residue in Figure 5. These data show that no water molecules are 
A C
DB
FigUre 5 | (a,B) The average number of water molecules per residue within ~4.5 Å of metastable/stable conformations of IR–TMD and IGF1R–TMD. 
(c,D) Selected snapshots from metastable/stable conformations of IR–TMD (c) and IGF1R–TMD (D) are shown to highlight interactions with water molecules 
(red licorice representations). Several charged residues in the termini of each peptide and a proline residue (961 for IR and 941 for IGF1R) are shown in brown 
and red space-filling representations, respectively. Each peptide is rendered as a cartoon in the same coloring scheme as in Figures 1 and 2.
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observed in the vicinity of helix-forming hydrophobic residues 
buried in the membrane (for example, 965–977 for IR–TMD and 
937–954 for IGF1R–TMD). Both IR–TMD and IGF1R–TMD 
have an “Arg–Lys–Arg” motif immediately following the TMD 
sequence that is exposed to solvent as indicated by the increas-
ing number of water molecules for residues in this motif of 
each peptide. Importantly, this motif is part of the unfolded 
C-terminus in IR–TMD but is fully folded in IGF1R–TMD. 
The exposure of this motif to solvent is compensated by a 
larger tilt angle in IGF1R–TMD in comparison to homologous 
sequence in IR–TMD. Several other residues in the C-terminus 
of each peptide have over 10 water molecules in their vicinity. 
A significant difference in water distribution is observed in the 
N-terminus of each peptide largely because residues 918–932 in 
IGF1R–TMD are highly flexible, unfolded, and located outside 
the membrane, while the homologous residues in IR–TMD form 
an α-helix resting at the membrane–solvent interface, such that a 
charged residue Lys956 has over 25 water molecules in its vicinity. 
The kink-forming residue Pro961 in IR–TMD is also significantly 
exposed to the solvent, but the corresponding residue Pro941 
in IGF1R–TMD is completely shielded from the solvent. The 
highest water density is observed for Arg966 in IGF1R–TMD, 
and for Lys956 or Arg982 in IR–TMD.
4. DiscUssiOn
In this work, we have presented all-atom structural models of 
51-residue long peptides containing the transmembrane domain 
sequence of IR and IGF1R (957–979 for IR and 936–959 for 
IGF1R; see Materials and Methods). These models have been 
generated in explicit membrane and solvent environments using 
MD simulations assisted by enhanced conformational sampling 
algorithms that facilitate extensive sampling of conformational 
space and provide information on key thermodynamic properties 
such as the free energy. For both receptors, we observe that the 
residues corresponding to the transmembrane domain sequence 
are fully membrane-embedded and form α-helices with a major 
kink at Pro961 in IR and a minor kink at Pro941 in IGF1R. A 
kink in IGF1R–TMD at Gly950 is unstable and recovers to an 
α-helical conformation. Based upon angle collective variables 
characterizing the orientation of each peptide in the membrane 
(Figure  4), we observe that the membrane-embedded α-helix 
in IGF1R–TMD is significantly more tilted (relative to the 
membrane normal) than in IR–TMD (Figures 5C,D). However, 
it is important to point out that these angles were not explicitly 
included as CVs in our metadynamics calculations and therefore 
were not extensively sampled. The values of angles reported in 
Figure 4 are those that correspond to extensive sampling along 
RMSD CV, as also indicated by multiple values of a specific angle 
corresponding to a single value of RMSD.
We also notice major differences in conformations of peptide 
termini: a short α-helix is observed for the N-terminal residues 
(939–958) of IR–TMD, but significantly unfolded and flexible 
conformations are observed for the N-terminal residues (918–932) 
of IGF1R–TMD, while an α-helix is observed for the C-terminal 
residues (960–968) of IGF1R, but unfolded and flexible confor-
mations are observed for the C-terminal residues (981–989) of 
IR. Importantly, irrespective of different conformations in the 
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C-terminus of each peptide, an “Arg–Lys–Arg” motif is solvent 
exposed, albeit at the expense of a larger tilt angle in IGF1R–TMD 
than in IR–TMD. However, we observe that all N-terminal resi-
dues (918–932) in IGF1R–TMD are solvent exposed, but only a 
few N-terminal residues (Lys956 and Pro961) in IR–TMD are 
significantly solvated. This difference is primarily due to the fact 
that a short α-helix in the N-terminus of IR–TMD is partially 
membrane-embedded such that the positively charged residues 
are oriented toward the membrane–solvent interface, while 
the N-terminal residues in many metastable conformations of 
IGF1R–TMD reside outside the membrane.
Li et  al. (49) have recently determined a solution structure 
of the transmembrane domain of IR (PDB code 2MFR) using 
NMR spectroscopy in dodecylphosphocholine (DPC) micelles. 
The following features observed in the NMR conformational 
ensemble are consistent with our IR–TMD structural models: 
(i) a well-defined α-helix (between residues Leu962 and Tyr976) 
buried in the DPC micelles with a kink at Gly960 and Pro961; 
(ii) a flexible and solvent-exposed C-terminal region (between 
residues Gln983 and Leu988); and (iii) a short α-helix (between 
residues Phe939 and Tyr944) partially buried in the DPC micelles 
with weak solvent interactions for Thr942 and Asp943. On com-
paring our models with the NMR structure, we observe that the 
kink angle at Pro961 in our IR–TMD models is larger than what 
is observed in the NMR structure, which results in increased 
interactions of Pro961 with the solvent in our models. We there-
fore analyzed the spherical micellar region encasing IR–TMD 
reported in Li et al.’s work (49) and found that it is at least ~3–4 Å 
thicker than the equilibrium thickness of a POPC membrane. We 
speculate that the difference in the hydrophobic thickness of a 
bilayer and a micelle could have contributed to a difference in the 
kink-angle near Gly960 and Pro961. However, the observation of 
a kink at these residues in our models and the NMR structure is 
consistent with the observation of enhanced helicity in IR–TMD 
on individual or simultaneous mutations of Gly960 and Pro961 
to Ala (75) as well as with the role of Gly and Pro residues as 
helix breakers (76, 77). Currently, no experimental structure of 
IGF1R–TMD is known, but consistent with our all-atom struc-
tural models of IGF1R–TMD, classical MD simulations reported 
in Kavran et al.’s work (32) indicate a kink at Pro941, interactions 
of His935 with the solvent, and a significantly tilted α-helical 
conformation of the transmembrane sequence.
A major unresolved question is related to the dimerization 
of IR–TMD and IGF1R–TMD in the basal or activated states of 
receptors in part because no experimental structures of these 
domains in a dimeric configuration have been reported so far. 
However, different models have been proposed (3, 30) by Ward 
et al. (10), Lee et al. (31), and Kavran et al. (32), as outlined in the 
introduction. For the isolated IR–TMD, Li et al. (49) primarily 
observed a monomeric conformation in the DPC micelles but 
suggested the possibility of a dimer with weak binding affinity 
because replacing IR–TMD with a strong dimer-forming TMD 
of glycophorin A (78) inhibits insulin signaling (26). For IGF1R–
TMD, Kavran et al.’s work (32) has suggested that IGF1R–TMD 
can form stable dimers by associating near kink-inducing residue 
Pro941 such that His935 residues in helices can interact with each 
other and the solvent. The conformations of helices reported 
in this dimer are consistent with our IGF1R–TMD structural 
models. Importantly, Cabail et  al. (33) have provided crystal-
lographic, biochemical, and biophysical evidence showing that 
the phosphorylated kinase domains of IR and IGF1R dimerize 
through exchanged juxtamembrane regions, but ~20 residues 
of unknown structure in the N-terminus of the juxtamembrane 
sequence preclude conclusive support for dimerized or dissoci-
ated transmembrane helices. While we have not directly studied 
the dimerization of IR–TMD or IGF1R–TMD in this work, the 
C-terminal sequences in our 51-residue long peptides include 
several residues from the N-terminal juxtamembrane regions 
of receptors (10 residues of IR and 9 residues for IGF1R). As 
described above, in both receptors, these residues are significantly 
exposed to the solvent, but adopt distinct conformations (in 
IR–TMD, completely unstructured and flexible conformations 
are observed as opposed to IGF1R–TMD, where these residues 
participate in an α-helix). We speculate that these conformational 
differences could contribute to different structural organization 
of kinase domains in the basal or activated states of receptors.
5. cOnclUsiOn
Using MD simulations combined with enhanced sampling 
algorithms, we have presented all-atom structural models of 
IR–TMD and IGF1R–TMD in explicit membrane and solvent 
environments. We found intact α-helical conformations for the 
membrane-embedded residues of each peptide with a larger 
tilt-angle (relative to the membrane normal) in IGF1R–TMD in 
comparison to IR–TMD. We also observe kinks in membrane-
spanning helices at Pro961 (IR) and Pro941 (IGF1R). The 
major differences in peptide conformations are in the terminal 
sequences where a kinked α-helix is observed for the N-terminus 
of IR–TMD as opposed to unfolded conformations in IGF1R, 
and an α-helix is observed in the C-terminus of IGF1R–TMD 
as opposed to unfolded conformations in IR–TMD. These dif-
ferences in conformations lead to increased solvation of the 
N-terminal residues in IGF1R–TMD in comparison to IR–TMD, 
but similar solvation patterns are observed in the C-terminal 
residues containing an “Arg–Lys–Arg” motif.
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